Published Date : 21 Jan 20 | Views: 105 | Industry : Life Science
Urinary FSH is likely to Boost the Growth of the Urinary FSH Segment
product segment is divided into Urinary FSH and Recombinant FSH. Both Urinary
FSH and Recombinant FSH are frequently used in ovarian stimulation, although several
studies have stated their effectiveness to be similar. The urinary preparation
FSH is said to be more cost-effective than the other, which is likely to
benefit the growth of Urinary FSH segment. The application segment is
classified into Assisted Reproductive Technology and Infertility treatment.
Rate of Adoption of Follicle Stimulating Hormone Products to Create Robust Growth in Europe Market
to the high rate of adoption of Follicle Stimulating Hormone products in Europe,
the region is expected to grab a remarkable share of the market in the years to
come. . On the other hand a high rate of infertility in females in North
America is driving the growth of the market in the region.
Companies to Focus on Investing in
of the key players operating in the Follicle Stimulating Hormone market are
MSD, Merck Serono, IBSA, Livzon, Ferring, Gensci, Techwell, Tev, and Gedeon
Richter. The market comprises several players, however, MSD and Merck Serono are
top companies generating a substantial amount of market revenue. The market
players are keen to invest in R&D to develop new products and to improve
Fertility Problems to Foster the Growth
of the Global Market
Growing ratio of infertility both in women and men due to the insufficiency of follicle-stimulating hormone has resulted in increasing Research and Development activityin the healthcare sector. Growing usage of Follicle Stimulating Hormone for FSH test to assess infertility problems amongst physicians is likely to foster the growth of the market. Follicle Stimulating Hormone test also helps in diagnosing disorders related to ovaries in the female population, which is contributing to the growth of the market.